Eligible patients were HLA-A*02 positive with advanced head and neck squamous cell carcinoma (HNSCC), melanoma, or urothelial carcinoma (UC) expressing MAGE-A10. The gene discussed is HLA-A; the disease is head and neck squamous cell carcinoma.